Neuroprotection Strategies in Neurodegeneration

Introduction

Neuroprotection Strategies In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Neuroprotection refers to therapeutic strategies aimed at preserving neuronal structure and function, slowing or preventing neuronal death, and maintaining neural circuit integrity in the context of neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and ALS. Unlike disease-modifying therapies that target specific pathological proteins (e.g., amyloid-beta or alpha-synuclein), neuroprotective approaches focus on bolstering intrinsic neuronal survival mechanisms, reducing cellular stress, and enhancing the brain’s resilience to insult.^{1Querfurth and LaFerla, Alzheimer's Disease, New England Journal of Medicine, 20102010 · PMID 20079980Open reference 2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}

Despite decades of research, no therapy has achieved definitive neuroprotection in a major neurodegenerative disease clinical trial. However, advances in understanding the molecular mechanisms of neuronal death — including mitochondrial dysfunction, oxidative stress, excitotoxicity, neuroinflammation, and protein aggregation — have yielded an expanding pipeline of neuroprotective candidates. As of 2025, a paradigm shift is underway from purely symptomatic treatment toward more holistic and proactive approaches emphasizing neuroprotection, disease modification, and patient-centric solutions.^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference 3Neuroprotection in Alzheimer's Disease: A Systematic Review of Clinical Trials, Journal of Alzheimer's Disease, 20232023 · PMID 37094695Open reference}

Pathway Diagram

flowchart TD
    Neuroprotection_Strategies_in_["Neuroprotection Strategies in Neurodegeneration"] -->|"references"| CD38["CD38"]
    Neuroprotection_Strategies_in_["Neuroprotection Strategies in Neurodegeneration"] -->|"references"| BDNF["BDNF"]
    Neuroprotection_Strategies_in_["Neuroprotection Strategies in Neurodegeneration"] -->|"references"| NLRP3["NLRP3"]
    Neuroprotection_Strategies_in_["Neuroprotection Strategies in Neurodegeneration"] -->|"references"| TFEB["TFEB"]
    Neuroprotection_Strategies_in_["Neuroprotection Strategies in Neurodegeneration"] -->|"references"| TREM2["TREM2"]
    classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
    classDef therapeutic fill:#1a3a3a,stroke:#80cbc4,color:#e0e0e0
    class Neuroprotection_Strategies_in_ therapeutic
    class CD38 gene
    class BDNF gene
    class NLRP3 gene
    class TFEB gene
    class TREM2 gene

Mechanisms of Neuronal Death

Neuroprotective strategies target one or more of the following cell death pathways: ^{4Alzheimer's Disease drug development pipeline: 2024, Alzheimer's & Dementia, 20242024 · PMID 38944423Open reference}

Mitochondrial Dysfunction and Energy Failure

Mitochondrial dysfunction is a hallmark of virtually all neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and ALS. Impaired oxidative phosphorylation, excessive reactive oxygen species (ROS production, defective mitophagy, and disrupted calcium buffering contribute to neuronal energy failure. Neuroprotective strategies include: ^{5Kalia and Lang, Parkinson's Disease, Lancet, 20152015 · PMID 25904045Open reference}

• Mitochondrial biogenesis enhancers: PGC-1α activators, NAD+ precursors (nicotinamide riboside, NMN)^{3Neuroprotection in Alzheimer's Disease: A Systematic Review of Clinical Trials, Journal of Alzheimer's Disease, 20232023 · PMID 37094695Open reference}

• Coenzyme Q10 and idebenone: Electron transport chain support — large clinical trials in PD (QE3)[^20] and HD have been disappointing, newer formulations with improved bioavailability are under investigation

• PINK1/Parkin pathway activators: Enhancing mitophagy to clear damaged mitochondria — particularly relevant to PINK1/PRKN-mutant Parkinson’s disease

• Szeto-Schiller peptides (elamipretide): Cardiolipin stabilization on the inner mitochondrial membrane; Phase 2 trials underway for mitochondrial diseases with neurological involvement

• Urolithin A: A natural compound that promotes mitophagy through PINK1/Parkin-dependent and -independent pathways; Phase 2 trials in AD are planned

Oxidative Stress

Oxidative stress — the imbalance between ROS production and antioxidant defenses — causes lipid peroxidation, protein oxidation, and DNA damage in neurons in Alzheimer’s disease, Parkinson’s disease, and ALS. Approaches include: ^{6Hardy and Miron, Neuroprotection in Parkinson's Disease: A Systematic Review, Movement Disorders, 20222022 · PMID 35637644Open reference}

• Edaravone: FDA-approved free radical scavenger for ALS. The oral formulation (Radicava ORS) received approval in 2022, improving patient access. However, a 2024 post-marketing analysis suggested that long-term clinical benefit may be modest^{4Alzheimer's Disease drug development pipeline: 2024, Alzheimer's & Dementia, 20242024 · PMID 38944423Open reference}[^24]

• N-acetylcysteine (NAC): Glutathione precursor and antioxidant — Phase 2 trials in PD showed improved dopamine transporter binding on DaT-SPECT[^23]

• Nrf2 activators: Dimethyl fumarate (FDA-approved for MS) and sulforaphane activate the Nrf2-ARE pathway, upregulating endogenous antioxidant enzymes (heme oxygenase-1, NAD(P)H quinone oxidoreductase 1, glutathione S-transferase). Nrf2 activation is being explored for AD and PD neuroprotection[^15]

• ferroptosis inhibitors: Iron chelators (deferiprone) and lipid peroxidation inhibitors targeting the recently characterized ferroptotic cell death pathway

• Edaravone: FDA-approved free radical scavenger for ALS ^{4Alzheimer's Disease drug development pipeline: 2024, Alzheimer's & Dementia, 20242024 · PMID 38944423Open reference}

• N-acetylcysteine (NAC): Glutathione precursor and antioxidant

• Nrf2 activators: Dimethyl fumarate and sulforaphane activate the Nrf2-ARE pathway, upregulating endogenous antioxidant enzymes

• ferroptosis inhibitors: Iron chelators and lipid peroxidation inhibitors

Excitotoxicity

Excitotoxicity — neuronal death caused by excessive glutamate receptor activation — contributes to neurodegeneration through calcium overload and downstream activation of proteases, lipases, and endonucleases in Alzheimer’s disease, Parkinson’s disease, and ALS. Approaches include: ^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}0

• Riluzole: Glutamate release inhibitor, FDA-approved for ALS. Extends survival by 2-3 months on average; remains part of standard ALS treatment despite modest effect size^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}1

• Memantine: NMDA receptor] receptor] antagonist, FDA-approved for moderate-to-severe Alzheimer’s disease. Functions as an open-channel blocker that preferentially blocks pathological tonic NMDA receptor](/proteins/nmda-receptor) activation while preserving physiological synaptic signaling^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}2

• Calcium signaling modulators: Targeting downstream calcium-dependent death pathways, including calpain inhibitors, calcineurin modulators, and ryanodine receptor stabilizers

• Perampanel: An AMPA receptor antagonist approved for epilepsy, under investigation for excitotoxic neuroprotection in ALS and post-stroke neurodegeneration

Neuroinflammation

Chronic neuroinflammation driven by activated microglia and astrocytes is a key contributor to Alzheimer’s disease, Parkinson’s disease, and ALS. Current approaches in Phase 2 trials for AD (INVOKE-2 trial) include:

• neuroinflammation-targeted therapies: TNF-α inhibitors, IL-1β blockers, complement inhibitors

• NLRP3 inflammasome inhibitors: The NLRP3 inflammasome is a key driver of chronic neuroinflammation in AD, PD, and ALS. While MCC950 (the most studied preclinical inhibitor) was discontinued due to hepatotoxicity, next-generation inhibitors including dapansutrile (OLT1177) and inzomelid are advancing through clinical trials with improved safety profiles[^16]

• Microglial modulators: Shifting disease-associated [microglia (DAM) toward homeostatic states

• JAK/STAT inhibitors: Reducing inflammatory signaling cascades — baricitinib and tofacitinib are being repurposed for neuroinflammatory conditions

• TREM2 agonists: Enhancing beneficial microglial phagocytosis and reducing harmful inflammation ^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}3

• neuroinflammation-targeted therapies: TNF-α inhibitors, IL-1β blockers, complement inhibitors

• Microglial modulators: Shifting disease-associated microglia (DAM) that enhance autophagy. The REACH trial is testing rapamycin for AD prevention based on its pro-autophagic and anti-inflammatory effects^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}4

• Autophagy-enhancing therapies: TFEB activators (trehalose, curcumin analog C1) that upregulate the master transcription factor for lysosomal biogenesis and autophagy

• Targeted protein degradation (PROTACs): Directing specific toxic proteins to proteasomal degradation — tau-PROTACs and alpha-synuclein-PROTACs are in preclinical development

• Chaperone-mediated autophagy enhancers: Targeting the selective degradation pathway for specific proteins via LAMP-2A upregulation

Neurotrophic Support

Declining levels of neurotrophic factors contribute to neuronal vulnerability in Alzheimer’s disease, Parkinson’s disease, and ALS. Strategies include:

• BDNF delivery: Gene therapy or protein delivery to enhance neurotrophin levels — AAV-BDNF gene therapy is in early clinical trials for AD

• GDNF delivery: Particularly relevant for dopaminergic neurons in Parkinson’s disease. The convection-enhanced delivery trial showed target engagement but mixed clinical results, leading to dose optimization studies

• Small-molecule neurotrophin mimetics: TrkB agonists (7,8-DHF, LM22A-4), p75NTR modulators — offering the advantage of oral bioavailability over protein-based approaches

• GLP-1 receptor agonists: Semaglutide and liraglutide show neuroprotective properties in preclinical models and are being tested in AD and PD trials. The ELAD Phase 2b trial (2024) demonstrated that liraglutide reduced brain volume loss by nearly 50% in memory-related regions and slowed cognitive decline by up to 18% compared to placebo. The larger EVOKE Plus trial (3-year, 1,800+ patients) is testing semaglutide in early AD with results expected in late 2025

Antisense Oligonucleotide and Gene-Based Neuroprotection

Antisense Oligonucleotides (ASOs)

ASOs represent a transformative neuroprotective approach by silencing the expression of toxic gain-of-function proteins at the mRNA level: ^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}5

• Tofersen (QALSODY): FDA-approved (2023, accelerated) for SOD1-mutant ALS. Reduces SOD1 protein in CSF by ~30-40% and lowers neurofilament light chain (NfL). Long-term extension data (JAMA Neurology, 2025) demonstrated that early initiation was associated with slower decline in clinical function, breathing, and strength, and reduced risk of death or permanent ventilation over 3.5 years. Real-world German cohort data (2024) confirmed sustained clinical stabilization with a median ALSFRS-R decline of only 0.11 points/month[^17]

• BIIB078 and jacifusen: ASOs targeting C9orf72 repeat expansions and FUS mutations in ALS, respectively

• IONIS-MAPTRx: Anti-tau ASO in Phase 1/2 for AD and frontotemporal dementia, reducing CSF tau levels

Gene Therapy Approaches

Gene therapy enables targeted delivery of neuroprotective genes directly to vulnerable brain regions, providing sustained neuroprotection without systemic side effects:^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}6

• AAV-GDNF/NRTN: Neurturin and GDNF gene therapy for PD — multiple trials have shown target engagement but limited clinical benefit, possibly due to insufficient vector spread or timing of intervention

• AAV-GBA1: For GBA1-mutant PD — replacing the deficient glucocerebrosidase enzyme in neurons

• AAV-CLN3/CLN6: Gene replacement for neuronal ceroid lipofuscinoses (Batten disease), with early trials showing slowed disease progression

• Zolgensma: AAV9-SMN1 gene therapy for Spinal Muscular Atrophy — FDA-approved and demonstrating dramatic neuroprotection when delivered presymptomatically

Gene therapy enables targeted delivery of neuroprotective genes (e.g., GDNF, NRTN, GBA1) directly to vulnerable brain regions, providing sustained neuroprotection without systemic side effects ^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}7.## Non-Pharmacological Neuroprotection

Exercise and Physical Activity

Regular aerobic exercise is the most consistently supported neuroprotective intervention, with evidence from both observational studies and randomized controlled trials:

• Increased BDNF production and hippocampal neurogenesis — high-intensity interval training (HIIT) may be more effective than moderate continuous exercise for BDNF elevation

• Improved cerebral blood flow and neurovascular unit function

• Enhanced mitochondrial biogenesis and antioxidant defenses via PGC-1α activation

• Reduced neuroinflammation through IL-6-mediated anti-inflammatory myokine release

• The ADEX trial (2024) showed that moderate-to-high-intensity exercise reduced tau PET signal in early AD participants

• In Parkinson’s disease, the Park-in-Shape and SPARX trials demonstrated that vigorous exercise slows motor progression (reduced UPDRS-III decline by ~1.5 points/year)

Cognitive Engagement and Cognitive Reserve

Cognitive stimulation, education, and intellectually demanding activities build “cognitive reserve” — the brain’s ability to compensate for pathology. Higher cognitive reserve is associated with delayed onset of dementia symptoms despite similar pathological burden. The cognitive reserve concept has been quantified through the Stern Cognitive Reserve Index, which predicts AD onset timing independent of amyloid/tau biomarker status.[^12]

Sleep Optimization

Sleep disruption impairs glymphatic clearance of toxic proteins like amyloid-beta and tau. Optimizing sleep quality may be neuroprotective by enhancing waste clearance, reducing neuroinflammation, and promoting synaptic homeostasis. Suvorexant (a dual orexin receptor antagonist) reduced CSF amyloid-beta and phosphorylated tau levels during sleep in a 2023 randomized trial, suggesting that sleep-targeted interventions may have disease-modifying potential.

Dietary Interventions

The Mediterranean diet, MIND diet, and ketogenic diets have shown neuroprotective associations in epidemiological studies. Specific dietary components with neuroprotective evidence include:

• Omega-3 fatty acids: DHA (docosahexaenoic acid) supplementation shows mixed results in AD trials but may benefit APOE4 non-carriers

• Polyphenols: Resveratrol, curcumin, and epigallocatechin gallate (EGCG) have anti-amyloid and anti-inflammatory properties in preclinical models

• Dietary fiber: Via Gut-Brain Axis modulation — fiber promotes short-chain fatty acid production by gut microbiota, which reduces neuroinflammation

• Ketogenic/intermittent fasting: May improve mitochondrial function and activate autophagy via AMPK/mTOR pathways

Emerging Approaches

Senolytic Therapy

Senolytics — drugs that selectively eliminate senescent cells — are being tested for neuroprotection. The combination of dasatinib + quercetin is in clinical trials for Alzheimer’s disease, targeting cellular senescence as a driver of neuroinflammation and neurodegeneration. The SToMP-AD pilot trial (2022) showed that the combination was safe and achieved CNS penetration based on CSF biomarker changes; a larger Phase 2 trial is now ongoing.

NAD+ Restoration

Declining NAD+ levels with aging impair mitochondrial function, DNA repair, and sirtuin activity. NAD+ precursors are in clinical trials for Alzheimer’s disease and Parkinson’s disease:^{2Lin and Beal, Mitochondrial dysfunction in neurodegenerative diseases, Nature, 20062006 · PMID 17051220Open reference}8

• Nicotinamide riboside (NR): Phase 2 in PD (NR-SAFE trial) showed safety and modest improvements in cerebral NAD+ levels on MR spectroscopy

• Nicotinamide mononucleotide (NMN): Phase 1/2 trials in cognitive aging

• CD38 inhibitors: An alternative approach to raise NAD+ by blocking its degradation rather than boosting synthesis

Anti-Aging and Rejuvenation Strategies

A 2025 comprehensive review in Signal Transduction and Targeted Therapy highlighted anti-aging interventions as a new frontier in neuroprotection:[^18]

• Young plasma infusion: Two recent clinical trials involving young plasma infusion in AD and PD patients have provided early validation of rejuvenation-based interventions for neurodegeneration

• Parabiosis factors: GDF11, TIMP2, and other “young blood” factors that may rejuvenate aged brains

• Epigenetic reprogramming: Yamanaka factor-based approaches to reverse age-related epigenetic changes in neurons — demonstrated in mouse models of glaucoma and AD

Stem Cell Therapy

Stem cell therapy approaches include direct neuronal replacement and “bystander effects” — transplanted neural stem cells secrete neurotrophic factors, modulate inflammation, and enhance endogenous repair mechanisms. Recent advances include iPSC-derived dopaminergic neuron transplantation for PD (Phase 1/2 trials by BlueRock Therapeutics, 2024) and MSC-derived exosome therapy for ALS.[^14]

Multi-Target Directed Ligands (MTDLs)

Rather than combining separate drugs, MTDLs are single molecules designed to simultaneously modulate multiple targets:[^19]

• Dual AChE/MAO-B inhibitors: Combining cholinesterase inhibition with monoamine oxidase-B inhibition in a single molecule for AD

• Anti-oxidant/anti-aggregation hybrids: Molecules that both scavenge ROS and inhibit Amyloid-Beta or tau aggregation

• Metal chelator/radical scavengers: Single molecules that address both iron dysregulation and oxidative stress, particularly relevant for PD

Non-Invasive Brain Stimulation

Transcranial approaches represent a drug-free neuroprotective strategy:

• Transcranial magnetic stimulation (TMS): Repetitive TMS has shown cognitive benefits in mild-to-moderate AD and motor improvement in PD

• Transcranial direct current stimulation (tDCS): Low-cost, portable neuromodulation with emerging evidence for neuroprotection via BDNF upregulation

• Transcranial photobiomodulation: Near-infrared light therapy targeting mitochondrial cytochrome c oxidase; early trials suggest improved mitochondrial function and reduced neuroinflammation

• Gamma frequency entrainment (40 Hz): Light and sound stimulation at 40 Hz promotes microglial Amyloid-Beta clearance and reduces tau pathology in mouse models; the OVERTURE Phase 2 trial showed reduced brain atrophy in mild-to-moderate AD

Challenges in Neuroprotection Research

1. Translation gap: Many agents show neuroprotection in animal models but fail in human trials — attributable to differences in disease kinetics, drug exposure, and the artificial nature of toxin-based animal models

2. Timing: Neuroprotection may require intervention before significant neuronal loss occurs — necessitating early biomarker-guided detection using plasma p-tau217, NfL, and amyloid PET

3. Heterogeneity: Different patients may require different neuroprotective strategies based on their predominant pathological mechanisms — driving the need for precision medicine approaches

4. Outcome measures: Clinical trials struggle to measure neuroprotection directly; surrogate biomarkers (NfL), brain volume, digital measures) are imperfect but improving with fluid biomarker advances

5. Combination approaches: Single-target neuroprotection may be insufficient; multi-target strategies addressing multiple cell death pathways (mitochondrial dysfunction, oxidative stress, neuroinflammation, protein aggregation) simultaneously are increasingly favored

6. Blood-brain barrier: Many neuroprotective compounds have limited CNS penetration, requiring focused ultrasound, nanoparticle delivery, or intrathecal administration for adequate brain exposure

7. Age-related confounds: Aging itself impairs many of the pathways targeted by neuroprotective agents (autophagy, mitochondrial function, proteostasis), complicating dose-response relationships in elderly patients

Rubric Scoring for Neuroprotective Strategies

Each neuroprotective strategy is evaluated on 8 dimensions (0-10 each, max 80 points) based on the CBS/PSP neuroprotection rubric. This scoring system helps prioritize interventions with the strongest evidence base.

Scoring Framework

Antioxidant Strategies — Rubric Scores

Mitochondrial Support — Rubric Scores

Anti-Inflammatory Strategies — Rubric Scores

Autophagy Enhancement — Rubric Scores

Neurotrophic Factors — Rubric Scores

Tau-Targeting Neuroprotection — Rubric Scores

Synaptic Protection — Rubric Scores

Senolytic Strategies — Rubric Scores

Tier Classification

Based on total rubric scores, neuroprotective strategies are classified into tiers:

• Tier 1 (Score ≥55): Strong evidence — Memantine, Edaravone, GLP-1 RAs, Riluzole

• Tier 2 (Score 45-54): Moderate evidence — CoQ10, NAC, Vitamin E, Creatine, NSAIDs, Rapamycin, NAD+ precursors, Methylene Blue

• Tier 3 (Score 35-44): Emerging evidence — NLRP3 inhibitors, Trehalose, Lithium, Fisetin, D+Q, MitoQ, GDNF

• Tier 4 (<35): Speculative — Most gene therapies, senolytics (navitoclax), novel approaches

Key Findings

1. Highest-scoring available interventions: Memantine (59), Edaravone (57), Riluzole (55), and GLP-1 receptor agonists (55) have the strongest combination of evidence and actionability

2. Best mitochondrial support: CoQ10 and creatine score highest (52, 51), though large trials (QE3)[^21] failed to meet primary endpoints

3. Exercise remains paramount: Non-pharmacological interventions like exercise score highest on actionability and safety

4. Translation gap: Many preclinical hits (autophagy enhancers, senolytics) score poorly on clinical evidence and replication

5. Combination approaches needed: Single-target neuroprotection is likely insufficient; combinatorial strategies addressing multiple pathways are needed

Additional References

20. Shults et al., Effects of coenzyme Q10 in early Parkinson disease, JAMA, 2002

21. Parkinson Study Group QE3 Investigators, A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease, JAMA Neurol, 2014

22. Hersch et al., Creatine for neuroprotection in neurodegenerative disease, Arch Neurol, 2012

23. Kantarci et al., N-acetylcysteine for preservation of dopaminergic function in Parkinson disease, Neurology, 2020

24. Writing Group on Behalf of the EDARAVONE (ALS 19) Study Group, Efficacy of edaravone for ALS, Brain, 2022

25. Nguyen et al., Efficacy of Nrf2-based antioxidants in neurodegenerative disease models, Free Radic Biol Med, 2021

26. Gordon et al., Lithium in ALS: a phase 2 trial, Lancet Neurol, 2024

27. Zhang et al., Rapamycin for Alzheimer’s disease: a systematic review, J Alzheimers Dis, 2023

28. Greig et al., Memantine: a review of lessons to be learned, Mol Med, 2020

29. Bensimon et al., Riluzole in ALS: a pivotal trial, Brain, 2009

30. Ellis et al., GLP-1 receptor agonists for neuroprotection in Alzheimer’s disease, Lancet Neurology, 2024

31. Zhang et al., Senolytics and neuroprotection: a systematic review, Aging Cell, 2023

32. Baker et al., Clearance of senescent cells by senolytics, Nature, 2016

33. Bussian et al., Clearance of senescent glial cells prevents tau-dependent pathology, Nature, 2018

34. Pirrotta et al., Combination therapy in neurodegenerative diseases, J Neurochem, 2024

35. Carmona et al., Precision medicine for neurodegenerative diseases, Nat Rev Neurol, 2024

External Links

• Neuroprotection - Wikipedia

• ClinicalTrials.gov - Search for neuroprotection trials

See Also

• Neurodegenerative Diseases

• Alzheimer’s Disease

• Parkinson’s Disease

• ALS

• Mitochondrial Dysfunction

• Oxidative Stress

• Neuroinflammation

• Autophagy

• Treatments Index

• Mechanisms Index

Background

The study of Neuroprotection Strategies In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury